PeptideStack
5.2kquestions
20kanswers
220users

Does splitting a 5 mg weekly dose of cagrilintide across two administrations change anything?

Asked 16 Jun 2024Modified 2.1 years agoViewed 6.1k times
11

What I am working with: 5 mg · cagrilintide.

I keep seeing this stated as a fact with no explanation attached, and unexplained facts make me suspicious.

My background is quantitative but not chemical, so I can follow an equation more easily than a hand-wave.

Why does this happen, and what would falsify the usual explanation?

split-dosing
split-dosing

Dividing a weekly dose across more than one administration. Questions here concern the pharmacokinetic rationale, whether the peak-to-trough ratio…

39 questionsdosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

811 questionsglp1-mechanism
glp1-mechanism

Receptor-level pharmacology: GLP-1R as a class B GPCR, cAMP and PKA signalling, biased agonism, internalisation and resensitisation, and the…

175 questions
shareeditfollowflag
LS
askedlow_dead_space42k3816 Jun 2024
I would add a sentence about sterility here, since it is the thing people skip. – Dr_Signe_Baldursdottir 8 months ago
The placebo-arm figure is the part everyone omits. – mz_4113 9 months ago
add a comment

No answers yet

This question has not been answered. It has been viewed 6.1k times, which suggests the question is of interest and the answer is not obvious. If you can answer it with a source or a worked calculation, it will be read. See how to ask and answer.
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.